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The theory of cancer stem-like cell (or cancer stem cell, CSC) has been established
to explain how tumor heterogeneity arises and contributes to tumor progression in
diverse cancer types. CSCs are believed to drive tumor growth and elicit resistance
to conventional therapeutics. Therefore, CSCs are becoming novel target in both
medical researches and clinical studies. Emerging evidences showed that nanoparticles
effectively inhibit many types of CSCs by targeting various specific markers (aldehyde
dehydrogenases, CD44, CD90, and CD133) and signaling pathways (Notch, Hedgehog,
and TGF-β), which are critically involved in CSC function and maintenance. In this review,
we briefly summarize the current status of CSC research and review a number of state-
of-the-art nanomedicine approaches targeting CSC. In addition, we discuss emerging
therapeutic strategies using epigenetic drugs to eliminate CSCs and inhibit cancer cell
reprogramming.
Keywords: cancer stem-like cell, induced pluripotent stem cells, epigenetic drugs, nanoparticle, combination
therapy
INTRODUCTION
While chemotherapy is one of the principal modes of cancer treatment, its effectiveness is limited
by drug resistance. The majority of patients with metastatic tumor eventually developing drug
resistance and succumbing to their disease. Resistance to chemotherapy can be divided into two
categories: intrinsic or acquired. Intrinsic resistance may be due to intratumor heterogeneity that a
minor drug resistance subpopulation of cells was present in the original tumor. The cancer stem-
like cell (or cancer stem cell, CSC) model provides an explanation for the phenotypic and functional
heterogeneity in some type of tumors. It has been proven that developing specific therapies targeted
at CSCs can improve the survival and quality of life of cancer patients, especially those with drug
resistance. Acquired resistance occurs as a result of genetic and epigenetic alterations that can alter
the sensitivity of the drug (Zahreddine and Borden, 2013). The high rate of epigenetic change in
tumor cells generates adaptive responses, such as increased therapeutic target gene expression and
activation of alternative compensatory signaling pathways. Moreover, epigenetic changes have also
been identified as important contributors to the cancer cell dedifferentiation and the non-CSC-to-
CSC conversion. Thus drugs targeting the epigenetic regulatory machinery (Biancotto et al., 2010)
may be an attractive option to re-sensitize to therapy.
Many strategies have been devised to specifically target CSCs, but with limited success
(Krishnamurthy et al., 2015a). But now nanoparticles (NPs) have been designed to specifically
and effectively target these hardy cells. A few reviews have discussed the therapeutic CSC
targeting strategies that have been employed in using nanocarriers delivering stem cell
signaling pathway inhibitors (Abetov et al., 2015; Hong et al., 2015). There is a scarcity
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of information, and many questions in this area remain
unexplored and unaddressed. Here, we summarize the current
status of CSC findings, the applications of therapeutic NPs in
targeting CSC and potential CSC epigenetic drug targets.
CSC THEORY AND DRUG RESISTANCE
In CSC theory or hypothesis, CSCs are those cells within
a tumor that can self-renew and cause the heterogeneous
lineages of cancer cells that comprise tumor (Bandhavkar,
2016). CSCs are highly resistant to conventional chemotherapies
owing to various enhanced features, including ATP-binding
cassette (ABC) transporter proteins, aldehyde dehydrogenase
(ALDH) activity, anti-apoptotic proteins, DNA damage repair
and activation of key pro-survival signaling molecules such as
Notch and NF-κB (Holohan et al., 2013). However, CSC research
faces many challenges. For example, reliable CSC markers have
not yet been established, and the stability of the CSC phenotype
is still being questioned. Therefore, elucidating CSC origin and
tumor cell plasticity will no doubt provide a better understanding
on CSC properties and help develop specific therapies targeted at
CSCs to improve the survival rate and the quality of life of cancer
patients.
CSC Origins
Whether CSCs arise from stem cells is currently under debate
(Figures 1A,B). One of the theories argues that CSCs may
arise from mutated stem cells because of the similarities
between them (Kumar and Kutty, 2012; Ma et al., 2014).
These two kinds of cells share similar cell surface markers,
naïve phenotypes, signaling pathways (Notch, Wnt, Hedgehog),
homing and migrating pathways in several type of cancers,
including leukemia and carcinomas of the breast, colon, liver,
lung, and pancreas (Vaz et al., 2013; Garcia-Montero et al.,
2016). If CSCs arise from the mutated stem cells present in
the adult tissue, they could simply utilize the existing stem-cell
regulatory pathways to promote their self-renewal (Hope et al.,
2004). Taking leukemia as an example, Dutta et al. (2015) inserted
the CALM/AF10 fusions gene, preceded by a loxP-flanked
transcriptional stop cassette, into the Rosa26 locus. They found
that Vav-Cre (VavCre-mediated recombination occurred in most
hematopoietic cells) induced pan-hematopoietic expression of
the CALM/AF10 fusion gene led to acute leukemia. However,
mice expressing CALM/AF10 in the B lymphoid compartment
using Mb1-Cre or CD19-Cre did not develop leukemia. These
results indicated that the ‘cell of origin of leukemia’ (COL)
for CALM/AF10 is a stem or early progenitor cell. There are
also similar findings in intestine cancer. Drost et al. (2015)
depleted four of the genes (APC, P53, KRAS, and SMAD4)
with CRISPR/Cas9 technology in cultured human intestinal
stem cells formed organoids. They found that quadruple
mutant stem cell organoids can grow with CSC properties
in vitro and as tumors with features of invasive carcinoma
in vivo.
Lineage committed progenitor cells can also function
like CSCs by means of epigenetics change, mutation, and
environmental factors participation, and behave as a cell of
origin of disease transformation. Recently, Buechele et al.
(2015) generated endogenous MLL-AF9 and MLL-ENL
oncogenes through insertional mutagenesis into primary human
hematopoietic stem and progenitor cells (HSPCs) derived
from human umbilical cord blood. They found the engineered
HSPCs induced acute leukemia following transplantation in
immunodeficient mice at 16 weeks.
Cancer stem cell may also be the product of dedifferentiation
of somatic cells from oncogenic insult, at least in breast cancer,
osteosarcoma, and colorectal cancer. For instance, Koren et al.
(2015) inserted PIK3CA(H1047R) mutation in the lineage-
committed basal Lgr5+ and luminal keratin-8+ cells of the adult
mouse mammary gland evoking cell dedifferentiation into a
multipotent stem-like. In osteosarcoma, Di Fiore et al. (2014)
found that the ectopic expression of p53-R248W/P72R in MG63
cells promoted cancer stem-like features suggesting that p53
gain of function can be at the root of the dedifferentiation
of MG63 cells into CSCs. Moreover, several studies showed
that colorectal cancer may arise from more differentiated
cells because of constitutive NF-κB activation (Myant et al.,
2013). Colorectal cancer also arises from a subpopulation of
differentiated quiescent tuft cells positive for DCLK1 upon
combined APC deletion and chemical-induced inflammation
(Westphalen et al., 2014). Taken together, these studies indicate
that CSCs can originate from non-stem cells at least in
certain types of cancer. Additionally, two of the fundamental
questions are which differentiated cells are susceptible to
mutation induced dedifferentiation and how this impacts
tumor progression and aggressiveness. We next summarize
the dynamic regulation of cancer cell plasticity which is
paramount for understanding tumor heterogeneity and CSC
origins.
CSC State Plasticity in Breast Cancer
The traditional hierarchical model believed that CSCs reside
in the apices of hierarchies and differentiate into non-CSCs
in a unidirectional manner (Chaffer et al., 2011). However,
CSCs might be alternatively derived from differentiated cancer
cells through different mechanisms, such as tumor niche
signals (Pattabiraman and Weinberg, 2014), cellular interactions
(Kim et al., 2010), and epithelial to mesenchymal transition
(EMT; Schieber and Chandel, 2013) (Figure 1C). The breast
CSC state plasticity is relatively well studied. It is found
that the bulk tumor cells are capable of “dedifferentiating”
into CSCs. Guo et al. (2012) showed that differentiated
breast cancer cells could be converted into stem-like cells
by overexpressing transcription factors SLUG and SOX9.
Furthermore, breast CSCs maintain the plasticity to transition
between two different phenotypic states: a more proliferative
epithelial-like state (ALDH+) and a more quiescent but invasive,
mesenchymal-like state (CD44+/CD24−). Transition between
the two CSC states is mediated by epigenetic alterations regulated
by microenvironment and EMT regulators (Brooks et al.,
2015).
In breast cancer, there is now rapidly accumulating evidence
showing that the EMT induction and acquisition of CSC
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FIGURE 1 | Stem cell and CSC downhill model (inspired by Waddington’s epigenetic landscape) showing cell fate plasticity. (A) A stem cell goes
through several steps to become differentiated cells (like a ball going downhill). The differentiated cells can be reprogrammed back into a pluripotent state (like hill
climbing) or into different lineage cells. (B) CSCs are capable of self-renewal and generation of differentiated progeny (like downhill). CSCs may arise from stem cells,
progenitor cells, or differentiated cells. (C) Increasing evidences indicated the cell fate plasticity between CSCs and non-CSCs. These conversions are dependent on
epigenetic regulation, gene expression patterns, as well as interactions with microenvironment.
characteristics are highly interrelated. The EMT is a highly
conserved cellular process that involves normal embryogenesis
and tissue repair (Liu and Fan, 2015; Ye et al., 2015). Through
an EMT process, tumor cells acquire mesenchymal properties
such as increased motility and invasion, which can endow cells
with stem-cell like characteristics. Phenotypically, breast CSCs
express high CD44 and low CD24 with increased ALDH1 activity.
Clinical evidences have shown that the CD44high/CD24low cells
were more enriched in triple negative (ER/PR- and HER2-) breast
cancer (TNBC) and were associated with increased risk for
metastases. Many efforts were made to illustrate the molecular
links between EMT regulators and breast cancer cell plasticity.
In 2013, Weinberg group found that ZEB1, a key regulator of
the EMT, can promote non-CSCs (CD44low) to enter the CSC
state (CD44high; Chaffer et al., 2013). Pharmacologic inhibition of
the Twist-BRD4 associated EMT suppressed CSC-like properties,
and tumorigenicity of basal-like breast cancer cells (Shi et al.,
2014). However, early studies focused on xenograft models
with ectopic expression of EMT factors that do not exist
under physiological conditions. In addition, EMT regulators
may have oncogenic functions independently of EMT induction,
thus observed phenotypes by gene manipulation may not be
exclusively due to EMT. Therefore, more effects are needed to
illustrate the importance of EMT in breast non-CSC-to-CSC
conversion.
Cancer cell plasticity can also be regulated by tumor niche
signals and cellular interactions. A number of studies have
demonstrated that a hypoxic niche may play an important role in
promoting the breast stem cell pool. Moreover, the relationship
between CSCs and their niches can be bi-directional. CSCs can
remodel the microenvironmental niches to facilitate survival,
stemness, and escape from chemotherapies (Pattabiraman and
Weinberg, 2014). Once a thorough understanding of how
dedifferentiation contributes to CSC traits has been achieved,
we can use this information to facilitate better therapeutic
treatments.
Similarities between Tumor
Dedifferentiation and Somatic Cell
Reprogramming
Induced pluripotent stem cell (iPSC) technology provides a high
efficiency and accessible technique to reprogram differentiated
cells into a pluripotent state (Takahashi and Yamanaka, 2006).
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A number of similarities exist between the processes of
reprogramming and tumor dedifferentiation (Semi et al., 2013).
First of all, although cells may appear phenotypically pluripotent
in certain experiments, premature or inaccurate reprogramming
at specific gene loci may generate undesirable cells, even be
tumorigenic (Figure 2A). Second, the reprogramming factors
(Oct4, Sox2, Klf4, and c-Myc) also play important roles in
tumorigenesis. Exactly as Oct4, the transcription factor which
also contributes to premalignant carcinoma in situ, as well as
high expressing in blastocyst and cancer cell cDNA but low
expressing in normal tissue cDNA (Vazquez-Martin et al., 2011).
Epithelial dysplasia in mouse cells that induced expression of
Oct4 provide further evidence for the important role of stem
cell genes in carcinogenesis (Beltran et al., 2011). Similarly, the
expression Nanog in Oral squamous cell carcinoma (OSCC)
indicates a poor prognosis, as well as nasopharyngeal carcinoma
if co-expressed with Oct4 (Li et al., 2013). Third, it was
demonstrated that several signaling pathways impacted the
reprogramming process by modulating small molecules such as
Wnt-β-catenin. Several studies have shown that Wnt/β-catenin
pathway activation is associated with poor outcomes in patients
with high-grade serous ovarian cancer (HGSOC; Nagaraj et al.,
2015). Wnt/β-catenin signaling is activated in ovarian CSCs,
and inhibition of β-catenin potently sensitized cells to cisplatin
and decreased CSC tumor sphere formation (Nagaraj et al.,
2015).
Generation of cancer-specific iPSCs provides a valuable
experimental platform to model oncogenesis like CSC and a way
to evaluate its potency. After reprogramming, the pluripotency
network can reduce aggressive cancer phenotype, which allows
early tissue differentiation and development sufficiently (Kim and
Zaret, 2015). The cells can re-acquire cancer phenotype along
with the re-differentiation, from which the lineage was derived
(Figure 2B). On this basis, Kumano et al. (2012) reported that
the iPSCs derived from a chronic myelogenous leukemia (CML)
patient were capable of re-differentiating into hematopoietic
cells effectively and recuperating sensitivity to therapeutic drug-
imatinib, which reiterated the pathophysiological features of
the initial disease (Kumano et al., 2012). Similarly, Jan E.
Carette reprogrammed a CML-iPS cell line that can derive
three germ layers in the process of teratoma formation (Carette
et al., 2010). The loss of the CML phenotype in CML-
iPS cells and the expression of pan-hematopoietic marker
CD45, stem cell marker CD34 and pan-T cell marker CD43,
indicating recover of differentiation potential. However, unlike
the parental cell line that was strictly dependent on BCR-
ABL oncogene signaling, the CML-iPS cell that had lost this
dependency will become resistant to the BCR-ABL inhibitor
imatinib. In the same way, Moore et al. (2015) established
the Ewing’s sarcoma (EWS)-iPS cells, and the hierarchical
cluster analysis demonstrated patterns of global methylation
similar to other ES and iPS cell lines. However, the EWS-
derived iPS cells may have been only partially reprogrammed
if the loss of DNA methylation is not achieved. Despite the
clones possessing many of the prototypical pluripotent markers
and phenotypic features, they fail to fully recapitulate the
developmental potential as they do from non-malignant tissues.
Whether it is a consequence of deficiencies in the reprogramming
method or an oncogene-mediated blockade of the proper
coordinated epigenetic alterations, remains unknown. Moreover,
a differentiated cancer cell can be reprogrammed to recapitulate
early-stage cancer and progression for discovering markers,
pathways, and therapeutics (Kim and Zaret, 2015). And then,
these pluripotent cells can redifferentiate into diverse cells, along
with the maintaining of inherited specific epigenetic marks or
some “epigenetic memory.” They prefer differentiating into the
lineage from which the iPS line was derived. In conclusion, cancer
is the outcome of multiple steps and comprehensive factors.
Thus, the fate-reversing model can replay the tumor process
in vitro.
NANOMEDICAL STRATEGIES FOR CSC
THERAPY
Cancer stem cells are highly resistant to standard conventional
chemo- and radio-therapies, and remain residual following
treatments (Lyakhovich and Lleonart, 2016). The mechanism for
high drug-resistance was mediated by diverse cellular processes,
such as entering into quiescence state (Li and Bhatia, 2011),
enhanced DNA damage repair (Sotiropoulou et al., 2014),
rapid drug eﬄux (Saha et al., 2012), over-expression of anti-
apoptotic proteins (Vinogradov and Wei, 2012), and detoxifying
enzymes (Vinogradov and Wei, 2012). Thus eliminating CSCs
has become a popular subject of current investigations. One
of the recent approaches to target CSC is the application in
the form of molecularly directed nanomedicine, which can
control drug delivery and release more efficiently. There have
been anticipated results in the early stage of clinical trials
that a nanocarrier can target and kill the cellular drivers
selectively and will alter the clinical management of cancer
fundamentally. NPs can sequester chemotherapeutic drugs at
a high concentration and release them within the cancer
cell following uptake by CSCs, which potentially overcome
such resistance mechanisms. The high target selectivity and
internalization will be achieved by targeting ligands on the
surface of NPs.
Nanoparticles can effectively inhibit multiple types of
CSCs by targeting specific markers (ALDH, CD44, CD90,
and CD133) and/or specific signaling pathways (Notch,
Hedgehog, transforming growth factor-β (TGF-β), and other key
developmental signaling pathways) that have been implicated in
the maintenance of the CSC pool of many tumors (Hong et al.,
2015).
Aldehyde Dehydrogenases (ALDH)
Marker
Recent studies have demonstrated that high levels of ALDH
activity are associated with enhanced tumorigenicity and
chemoresistance in many cancers (Li D. et al., 2015), such as
cervical cancer (Liu and Zheng, 2013), non-small cell lung cancer
(Shao et al., 2014), and melanoma (Yue et al., 2015). Li S.Y. et al.
(2015) have developed NPs encapsulating low-dose decitabine
that can sensitize CSCs with high ALDH activity [ALDH (hi)]
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FIGURE 2 | Modeling cancer with cellular reprogramming technology. (A) Premature termination of reprogramming leads to tumor development.
(B) Re-differentiation of cancer cell-derived iPSC can recapitulate the progression of human cancer development.
to chemotherapy. The NPs were prepared with biodegradable
MPEG-b-PLA, which can easily load small molecule drugs
such as doxorubicin (DOX) and decitabine (NPDAC). NPDOX
were prepared using single emulsion method, and the average
diameter was 88.8 ± 2.7 nm. NPDAC were fabricated using the
double emulsion method, resulting in a narrow size distribution
(79.8 ± 2.3 nm), and the drug loading (DL) and encapsulation
efficiency (EE) of DOX were 5.0 and 51.8%, respectively. The DL
and EE of NPDAC were 1.0 and 3.7%, respectively. In vitro studies
revealed that treatment with NPs loaded with low-dose decitabine
combined with NPs loaded with NPDOX better reduced the
proportion of CSCs with ALDH (hi) in the mammospheres of
MDA-MB-231 cells, and better overcame the drug resistance by
ALDH (hi) cells.
CD44 Marker
The receptor CD44 was strongly expressed by the CSCs; it is a
signaling platform that integrates cellular microenvironmental
cues with growth factor and cytokine signals. Accumulating
evidence indicates that CD44, especially CD44v isoforms, are
CSC markers and critical players in regulating the properties
of CSCs, including self-renewal, tumor initiation, metastasis,
and chemoradioresistance (Yan et al., 2015). Aires et al.
(2016) successfully applied novel multifunctionalized iron oxide
magnetic NPs (MNPs) with antiCD44 antibody and gemcitabine
derivatives for the selective treatment of CD44 positive cancer
cells. The results confirmed the selective drug delivery potential of
the MNPs by the killing of CD44-positive cancer cells using CD44
negative non-tumorigenic cell lines as control in pancreatic and
breast cancers cell lines. MNPs have two advantages compared
with other nanoplatforms; they can be used to kill cancer cells
through hyperthermia and act as contrast agents in MRI (Aires
et al., 2016).
CD90 Marker
CD90 is a glycosyl phosphatidylinositol-anchored membrane
glycoprotein of the immunoglobulin superfamily (Haeryfar
et al., 2005), it has been identified as a marker for CSCs
such as hepatocellular carcinoma (HCC; Luo et al., 2015),
and osteosarcoma (Chen et al., 2015), which are responsible
for tumorigenic activity. Luo et al. (2015) isolated CD90+
cells from hepatoma carcinoma cell (HCC) lines that exhibited
increased tumorigenicity, chemoresistance, tumor invasion, and
metastasis. Notch pathway was activated in CD90+ cells
and researchers found that inhibition of Notch pathway in
CD90+ CSCs decreased tumorigenicity, cell invasion, migration,
and expression of stem cell related genes. Activation of the
Notch pathway in CD90− cells induced self-renewal, invasion,
and migration. Furthermore, Luo et al. (2015) observed
that the CSC features were facilitated by stimulating G1-S
transition in the cell cycle phase and inhibited apoptosis
mediated by the Notch pathway. Yang et al. (2008) loaded
photosensitizers trifluoperazine in anti-CD90 antibody-mediated
water-soluble CdSe core nanocrystals to target the CD90+
leukemia CSCs specifically; it showed leukemia CSCs sensitized
to UV irradiation and leaving apoptotic cell death (Bakalova et al.,
2004).
CD133 Marker
The stem cell marker CD133, also known as prominin-1, is
a transmembrane glycoprotein. The protein overexpresses in
various cancer types, including metastatic colorectal cancer,
ovarian cancer, glioblastoma, and gastric carcinoma. Ni et al.
(2015) developed salinomycin-loaded PEGylated poly (lactic-co-
glycolic acid) NPs (SAL-NP) conjugated with CD133 aptamers
(Ap-SAL-NP). SAL-NP had an average size of 133.4 nm,
whereas Ap-SAL-NP had a slightly larger size of 159.8 nm,
indicating that the modification of CD133 aptamers increases
the size of SAL-NP. The polydispersity index (PDI) of the
NPs is smaller than 0.2, suggesting that the size distribution of
these NPs is narrow. The proportion of CD133+ osteosarcoma
cells in the excised tumors was significantly reduced by Ap-
SAL-NP treatment compared with salinomycin and SAL-NP,
which demonstrated that Ap-SAL-NP has the potential to
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effectively target and eliminate CD133+ osteosarcoma CSCs both
in vitro and in vivo (Ni et al., 2015). More recently, loading
chemotherapeutic antitumor drugs and siRNA into Mesoporous
silica NPs (MSNPs) which are of thermo/pH-coupling sensitivity
and site-specificity, were successfully delivered into CD133+
cancer cells in laryngeal cancer mouse mode (Qi et al.,
2015).
Notch Signaling Pathway
Notch signaling, a key regulator of stem cells, frequently sustains
activation in many cancers. It often relates to aggressive,
evading standards, so that highlighting Notch appears an
exciting therapeutic target. The pathway, in principle, can be
blocked by γ-secretase inhibitors (GSIs), inhibitory peptides
and antibodies, in principle; however, clinical use of Notch
inhibitors is restricted by severe side effects. Therefore,
conjugated with imagable ligands, MSNPs loaded GSIs system
was used to control the delivery of GSIs to target the
Notch pathway efficiently. A recent study suggested that
inhibition of Notch signaling sharply decreased self-renewal,
clonogenic, and the tumorigenic potential of glioblastoma
CSCs (Chenna et al., 2012). In addition, inhibition of Notch
signaling led to a decrease of the CSC-like subpopulation
and increased the susceptibility of CSCs to radiation-induced
apoptosis in glioblastomas. Aberrant activation of Notch
signaling has been observed in CD133+ liver CSC subpopulations
when compared with CD133− subpopulations (Zhu et al.,
2015).
Hedgehog (Hh) Signaling Pathway
Similarly, the Hedgehog (Hh) signaling pathway is a critical
regulator during early development and regeneration. It is
also identified as an important regulator in cell differentiation,
growth, and migration. Mutations in different components of
sonic hedgehog (Shh) pathway can lead to the development
of many cancers including melanoma, medulloblastoma,
rhabdomyosarcoma, basal cell carcinoma, breast, lung, liver,
pancreas, and prostate cancers (Tang et al., 2012; Verma et al.,
2015). Almost currently available Hh small-molecule inhibitors
approved for trials for cancer therapy are Smo antagonists.
However, clinical application was restricted by their limited
binding ability to Smo and poor systemic bioavailability.
Using anthothecol which acted via the Sonichedgehog
signaling pathway, Verma et al. (2015) developed anthothecol-
encapsulated PLGA-NPs (Antho-NPs) to regulate the behavior
of pancreatic CSCs. The result shows Antho-NPs significantly
reduced the ability of cell proliferation and colony formation,
and induced apoptosis in pancreatic CSCs. No effect was
observed in normal pancreatic ductal epithelial cells (Verma
et al., 2015).
Transforming Growth Factor-β
Transforming growth factor-β signaling is an important
prognostic marker in various types of cancer. While the
oncogenic effects of TGF-β in several types of tumors are
well-documented, its potential role in CSCs has only recently
emerged; selective targeting of TGF-β signaling may be
considered as an effective therapeutic strategy for the treatment
of various types of cancer. Synergistic treatment with a NP drug
delivery system, loading TGF-β signaling pathway inhibitor
enhanced tumor penetration and CSCs clearance in vivo. Zuo
et al. (2016) had constructed cationic lipid-assisted polymeric
NPs with siRNA encapsulation using a double emulsion method,
and the NPsiRNA showed sustained and sufficient cumulative
release of siRNA, Combined siRNA and LY364947, which is
a TGF-βR-I inhibitor, act as a penetration enhancer in NPs;
the work showed remarkable tumor regression and a notable
decrease in CSC frequency (Zuo et al., 2016). Huan Meng
developed a nanocarrier, which, used a polyethyleneimine
(PEI)/polyethylene glycol (PEG)-coated MSNP for molecular
complexation to a small molecule TGF-β inhibitor, LY364947.
Because of the high loading capacity and pH dependent
LY364947 release from the MSNPs, the platform facilitates
systemic biodistribution and retention at the tumor site (Meng
et al., 2013).
Collectively, these studies suggest that targeting signaling
or markers by various nano-carriers might be an effective
therapeutic approach in patients with recurrence following
curative surgical resection, as well resistance to chemotherapy.
NANOPARTICLE PLATFORMS FOR
CSC-TARGETED DRUG DELIVERY
Unlike conventional chemotherapy, NPs have their distinctive
and multifunctional properties and various physicochemical
structures that carry chemotherapeutic drugs at a high
concentration, releases them when arriving at the destination
and are uptaken by CSCs. The addition of targeting ligands
to the surface of NPs may increase both target selectivity
and internalization. In order to accommodate multifarious
environment in vivo, a huge diversity of NP platform has been
developed to contain different sizes, configurations, chemical
properties, and biofunctional compositions. In the following
section, we will summarize the most widely studied organic and
inorganic NPs in current researches (Table 1).
Liposomes
Liposomes were defined as spherical polymeric vesicles consisting
of an aqueous core surrounded by one or more concentric
phospholipid layers. It shows a wide range of potential
application as they are able to carry hydrophilic, hydrophobic,
and amphiphilic molecules, as well as are easily manipulated
during their production process.
Yang et al. (2008) have developed a novel liposome
formulation bearing anti-CD44 antibody to target a bellicose
hepatocellular CSC with high tumorigenicity and metastatic
potential that over expressed CD44. Doxorubicin were loaded as
model drug in targeted liposomes and then injected intravenously
into tumor-bearing mice, resulting in a sevenfold higher drug
concentration in tumors compared with free DOX, which
caused smaller tumor volume. Encouragingly, this effect was
achieved by little changes in mouse body mass. Injection of
free drug generated similar results in tumor burden but with a
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TABLE 1 | List of NPs targeting CSC through specific markers or signaling pathways.
Type of nanoparticle Target Anticancer agent Type of cancer Reference
Liposomes Nucleolin, CD44 F3 peptide, γ-secretase inhibitors (GSIs), Tamoxifen,
Paclitaxel
Triple negative breast cancer
(TNBC)
Parvani et al., 2015
Micelles ALDH1A1, CD44 Paclitaxel (PTX), anti-CD44 antibodies, Cetuximab
(anti-EGFR), phenformin, gemcitabine, thioridazine
(THZ), Twist1 siRNA
Breast cancer, lung cancer Gener et al., 2015;
Krishnamurthy et al.,
2015b
Polymeric nanoparticles ALDH, CD133 Hedgehog pathway inhibitor (HPI) Brain tumor Lim et al., 2011;
Chenna et al., 2012
Gold nanoparticles TGF-β, acid-labile
hydrazone bond
Doxorubicin Breast cancer Sun et al., 2014
significantly high loss of body mass (>30%) in exposed animals.
Alternatively, the authors could accomplish tumor imaging and
gene therapy at the same time to treat the cancer by using the
targeted liposome to carry a triple fusion plasmid, involving gene
expression cassettes for red fluorescence protein (RFP), renilla
luciferase (Rluc), and a truncated herpes simplex virus thymidine
kinase (HSV-TTK) gene. Treatment with the combination of
HSV-TTK liposome and ganciclovir (a cytotoxic thymidine
kinase substrate) caused a robust increase in tumor-localized
apoptosis with trifling effect on normal tissues in tumor-bearing
mice.
The example of treatment of CSC in breast cancer was
reported by Parvani et al. recently, based on the research
that surface nucleolin overexpression could be associated
with the identification in highly tumorigenic triple negative
breast cancer (TNBC) cells (Parvani et al., 2015). They
have developed an F3 peptide-targeted liposomal strategy,
targeting cell surface nucleolin, and 100% cell deaths were
observed under the proposed link between the stem-like
phenotype nucleolin expression in TNBC and F3 peptide-
targeted synergistic drug combination, rendering 100% cancer
cell death. These findings suggest the potential to abolish
the plasticity and adaptability associated with CSC. Ahmad
A developed dexamethasone-associated liposomal formulation
(DX) that can selectively manipulate glucocorticoid receptor
(GR) of cancer cells and release its cargo. Dexamethasone
(Dex) is a well-established synthetic ligand for the GR.
Due to its structural similarities with cholesterol, Dex was
directly incorporated alongside cholesterol and cationic lipid
to get a DX liposomal formulation. The resultant liposomal
formulation of dexamethasone (Dex)-associated liposome (DX)
can encapsulate and deliver the anticancer drug ESC8. The
results showed this dual-drug loaded liposomal formulation
was able to sensitize and kill highly aggressive and drug-
resistive breast cancer stem-cell-like cells, ANV-1 (Ahmad et al.,
2016).
Micelles
Micelles are core-shell NPs with a hydrophobic core and a
hydrophilic exterior, which are formed from the self-assembly
in aqueous media of lipids or other amphiphilic molecules that
range in size from 20 to 200 nm in diameter.
Gener et al. (2015) developed a permanent CSC tagging
which permits the identification and separation of CSC from
heterogeneous populations by using an ALDH1A1/tdTomato
reporter vector. Thereafter, they investigated the efficacy
of poly [(D,L-lactide-co-glycolide)-co-PEG] (PLGA-co-
PEG) polymeric micelles loaded with paclitaxel (PTX);
the MS,PI,ZP of PLGA-co-PEG-PTX-CD44, respectively,
are 11.67 ± 0.05 nm, 0.037, –5.62 ± 0.41 mV in day 0,
8.52± 0.08 nm, 0.043, –5.88± 0.01 mV on day 60. Transmission
electron micrographs showed monodisperse micelles with a
spherical shape with average diameters that correlated with
the hydrodynamic measures obtained by DLS. Stability assays
confirmed that this concentration remained constant until day 7,
functionalized with CD44 antibodies in breast, and Cetuximab
(anti-EGFR) in colon cancer cell lines. The results showed that
specific active targeting toward surface receptors enhances the
performance of nanomedicines and sensitizes CSC to paclitaxel
based chemotherapy.
In another study, Krishnamurthy et al. (2015b) loaded
phenformin, capable of eliminating CSCs into micelles via
self-assembly using a mixture of a diblock copolymer of
poly (ethylene glycol; PEG) and functionalized polycarbonate
and a diblock copolymer of PEG and acid-functionalized
polycarbonate through hydrogen bonding. The phenformin-
loaded micelles (Phen M) were more effective in inhibiting
the growth of both lung CSCs (side population cells, i.e.,
SP cells) and non-SP cells. Interestingly, the same group
recently further showed that Phen M in combination with
gemcitabine-loaded micelles (Gem M) exhibited higher
cytotoxicity against lung CSCs and non-CSCs than Gem
M and Phen M alone without inducing toxicity to the
liver and the kidney. Similarly, micelle was loaded with
thioridazine (THZ), which was reported to kill CSCs, in a
combination therapy with DOX to eradicate both breast
cancer cells and DOX-resistant breast CSCs (Ke et al.,
2014).
Furthermore, micelles can be structurally and chemically
modified to respond to various environmental stimuli such as a
pH-triggering release behavior of the DOX-loaded mixed micelle
(DLMM), which releases faster in acidic media (pH 4.0–6.0). For
example, Yu et al. (2016) recently reported a novel triple-layered
pH-responsive micelleplex loading siRNA and alkylated cisplatin
prodrug for treatment of metastatic breast cancer. Such pH-
sensitive, stable, and biocompatible nanocarriers are extremely
attractive for biosensing and therapeutic applications of CSCs
targeting.
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Zhang et al. (2012) developed a novel polymeric micelles
simultaneous delivery of paclitaxel and salinomycin. Salinomycin
can efficiently reduce the CSC population when compared with
paclitaxel. A diblock copolymer of poly(ethylene glycol) and
poly(ε-caprolactone; PEG-b-PCL) was used to produce micelles
and the drugs were loaded into the micelles separately. To target
somatostatin receptors overexpressed in cancer cells, paclitaxel-
loaded micelles were further wreathed with octreotide. The
range in size of micelles is 25–30 nm, which was noticeably
smaller than the abovementioned liposomes, thus their ability
to gather in tumors via the EPR effect is increasing. In vitro
the co-delivery of paclitaxel-loaded and salinomycin-loaded
micelles killed MCF-7 cells and their effect was comparable
to the free drug combination. Yet, in vivo findings on MCF-
7 mouse xenografts are interesting. The drugs loaded micelles
possessed significantly higher anti-tumor effects than the free
drugs. The reason for that could be the enhanced buildup of
drug-loaded micelles in the tumor site and prolonged drug
release.
Polymeric Nanoparticles
Polymeric NPs have emerged as a valuable nanotechnology
platform for controlled, sustained, and targeted delivery
of anticancer agents including small molecular drugs, and
macromolecules such as genes and proteins may be the best NPs
for long-term therapeutic delivery.
Recently Chenna et al. (2012) have developed a polymeric
NP loaded with a small molecule inhibitor, HPI-1 (Hh pathway
inhibitor), which was shown to overcome the secondary
mutational resistance toward Smoothened antagonists. Hh
signaling is believed to be abnormally active in most of
the human cancers, and Smo secondary mutation annuls the
binding of most of the Hh inhibitors. The group tackle this
problem by nanoformulating HPI-1 (NanoHHI) that is a strong
antagonist of Gli1 and found that NanoHHI strikingly inhibits
the growth of mouse medulloblastoma allografts, which shelter
a SmoD477G-binding site mutation, together with substantial
downregulation of Gli1 mRNA. Nanoformulation of HPI-1
increased its water solubility and systemic bioavailability as
well (Chenna et al., 2012). The same group of researcher
also verified their studies in an orthotopic model by using
NanoHHI to check if the inhibition of Hh signaling in
HCC is made. NanoHHI significantly diminished systemic
metastases in HCC cell lines both in vitro and in vivo.
Additionally, it also reduced the population of CD133+-
expressing HCC cells, which were regarded as the tumor-
initiating cells.
In a research by Lim et al. (2011), they studied the efficacy
of a patented polymer-encapsulated curcumin NP formulation
(termed NanoCurcTM) for the treatment of brain tumor stem
cells. The NP formulation greatly increased the bioavailability
of curcumin, and increased rates of cell cycle arrest, apoptosis,
and dosedependent decreases in growth and clonogenicity were
observed after treatment of four distinct brain cancer cell lines
with NanoCurcTM. Interestingly, this treatment correlated with
a >50% reduction in the CD133+ stem cell population in two
of the cell lines tested, suggesting that this therapy may have its
influence in the CSC fraction of some brain tumors (Lim et al.,
2011).
Gold Nanoparticles
Gold NPs (AuNPs) are composed of self-assembled gold atoms
that range in size from 1–150 nm in diameter. Proper utilization
of gold as nano-sized particles has been investigated in the recent
years with the advancement of nanoscience and technology.
Recently, to decorate the surface of AuNPs with poorly
self-interacting polymers, Sun et al. (2014) developed a well-
elucidated method to rationally design AuNPs. The NP was
coated with DOX via a poly (ethylene glycol) spacer and an
acid-labile hydrazone bond that can mediate efficiency DOX
delivery to breast CSCs. The DOX-Hyd@AuNPs showed efficient
DOX transportation to cancer cells as well as responsive
intracellular drug release which can reduce their mammosphere
formation capacity and their cancer initiation activity, eliciting
marked enhancement in tumor growth inhibition in murine
models (Sun et al., 2014). Xiong et al. (2014) reported that
AuNPs prevented cisplatin-induced acquired chemoresistance
and stemness in ovarian cancer cells and sensitized them to
cisplatin. They demonstrated that 20 nm AuNPs inhibited
proliferation, angiogenesis, and metastases in a preclinical
mouse model of ovarian cancer. Mechanistically, AuNPs
prevent cisplatin-induced activation of Akt and NF-κB signaling
axis in ovarian cancer cells that are critical for EMT,
stem cell maintenance, and drug resistance (Xiong et al.,
2014).
Tsai et al. (2013) found that AuNPs could selectively capture
TGF-β1 through S–Au bonds which was proved using X-ray
photoelectron spectroscopy. The binding between cysteine and
disulfides residues resulted in the deactivation of the TGF-β
signaling pathway. The bond strength of free cysteine (-SH) on
the side chain was slightly less than that of disulfide (S–S), which
is attributed to the formation of two S–Au bonds. TGF-β has
been implicated as a “master switch” in the induction of fibrosis
in many tissues, and plays a key role in the EMT with different
isoforms mediating various effects. After getting captured by
AuNPs, TGF-β1 undergoes significant conformational changes at
both secondary and tertiary structural levels after conjugation to
the AuNP surface, which results in the deactivation of TGF-β1
protein (Tsai et al., 2013).
Atkinson et al. (2010) recently found local hyperthermia
achieved by gold nanoshells plus radiation can eradicate
radioresistant breast CSCs. Using both syngeneic mouse and
human xenograft models of triple-negative breast cancer, the
same group has demonstrated that a subpopulation enriched
in CSCs was more resilient to treatment with six gray
of ionizing radiation than the bulk of the tumor cells
(Atkinson et al., 2010). In contrast, they found a larger
decrease in tumor size without an attendant increase in the
percentage of CSCs when treating with local hyperthermia for
20 min at 42◦C after ionizing radiation using intravenously
administered, optically activated gold nanoshells. After 48 h
treatment, cells arose from the tumors treated with ionizing
radiation plus hyperthermia demonstrated both a significant
reduction in tumorigenicity and a more differentiated phenotype
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than mock- and ionizing radiation-treated tumors. Therefore,
they have confirmed that gold nanoshells plus radiation are
responsible for eliminate these CSCs in vivo and demonstrated
that hyperthermia sensitizes this cell population to radiation
treatment.
EPIGENETIC DRUGS, CSC TARGETING,
AND NANOPARTICLE
Global epigenetic changes, such as DNA methylation and Histone
modifications, have been associated with the de/differentiation
of normal stem cells and cancer cells. However, the role
of epigenetic drugs on CSCs remains under investigation.
Epigenetic regulators that carry out different functions can
be thought of as being either “writers,” “readers,” or “erasers”
(Schnekenburger et al., 2016). Most drugs have been developed
to target “writers” and “erasers.” It is well known that Valproic
acid (VPA), a histone deacetylase inhibitor, can potently inhibit
tumor growth and induce differentiation. Lee et al. (2015)
showed that VPA inhibited the self-renewal abilities of head
and neck squamous cell carcinoma (HNSCC) CSCs during
two serial passages and reduced the expression of stem cell
markers, such as Oct4, Sox2, and CD44 (Lee et al., 2015).
Sakaki et al. (2015) reported that the H3K27me3 demethylase
JMJD3 inhibitor, GSKJ4 induced cell death, loss of self-
renewal, and tumor-initiating capacity of ovarian CSCs. NPs
should minimize drug release in vivo during blood circulation
and trigger intracellular delivery through endocytosis, holding
promises for increased efficacy of this class of epigenetic
inhibitors.
Furthermore, epigenetic “reader” inhibitors, such as
bromodomain and extra terminal protein (BET) inhibitors
are delivering a novel promising therapeutic opportunity by
directly targeting bromodomain proteins (such as BRD4) that
bind acetylated chromatin marks. Dawson et al. (2011) showed
that GSK1210151A (I-BET151), a novel small molecule inhibitor
of the BET family, has profound efficacy against MLL-fusion
leukemic cells. Later, Wyspian´ska et al. (2014) reported that
a specific BET family bromodomain inhibitor, I-BET151, led
to growth inhibition in a human erythroleukemic (HEL) cell
line isolated from polycythemia vera patients. Another group
also reported that treatment with I-BET151 reduced GBM
cell proliferation in vitro and in vivo (Pastori et al., 2014).
Unfortunately, BET inhibitor resistance emerges because of
leukemia stem cells as reported by Dawson group (Fong et al.,
2015). They used primary mouse HSC immortalized with
the fusion protein MLL-AF9 to demonstrate resistance to
the prototypical BET inhibitor, I-BET. They further showed
that resistance to BET inhibitors is in part a consequence of
increased Wnt/β-catenin signaling. Although BET inhibitors
have limitations, a combination or nanocarrier strategies may
enhance the clinical utility of these targeted therapies.
Epigenetic drugs might be a potential therapeutic strategy in
combination with conventional chemo-drugs for drug resistant
patients by elimination of CSC traits. For example, decitabine
(DAC), which is a DNA hypermethylation inhibitor, is an
attractive approach to enhancing the chemotherapeutic response
and overcoming drug resistance by CSCs. Li S.Y. et al. (2015)
showed that treatment with NPs loaded with low-dose DAC
(NPDAC) combined with NPs loaded with DOX (NPDOX)
better, and reduced the proportion of CSCs with high ALDH
activity in the mammospheres of MDA-MB-231 cells. In
another recent study, Unland et al. (2015) showed that the
pharmacological inhibition of EZH2, an H3K27me3 methylase,
synergistically affects the antitumor activity of the epigenetic
compounds 5-Aza-CdR and SAHA. Moreover, Matkar et al.
(2015) found that an epigenetic pathway involving MLL2 is
important for growth of HER2+ cells and sensitivity of the
cancer cells to a HER2 inhibitor, lapatinib. These findings
indicate the potential therapeutic strategy using MLL2 inhibitor
in combination of lapatinib delivered by nanocarrier to treat
metastatic breast cancer patients (Matkar et al., 2015).
CONCLUSION
There is a significant increase in targeting CSCs with the
use of NPs-based drug, protein, or nucleic acid delivery.
However, a few of the roadblocks of NPs have not yet been
overcome. First, CSC targeting is a tricky science, and success
in targeting CSCs in vitro might not always translate to
success in vivo. There are obvious limitations in reaching the
CSCs in vivo owing to inaccessibility of the entire tumor area
and microenvironmental factors, which may be circumvented
by using environmentally sensitive NPs (such as pH and
reduction potential, among others). Also, it is important to
better understand the key characteristics of CSCs in order to
target them effectively. For example, CSCs always remain a
scarce population within a tumor but are able to repopulate
when inoculated in a new environment, indicating that there
is some level of organization within the apparent anarchy.
Knowing the factors that dictate the fate of CSCs can greatly
change the way they are targeted. Second, the field of CSCs
is relatively new and there are no well-established protocols to
distinguish and separate them. Different researchers use different
surface markers and biochemical assays for identification. This
should be standardized so that therapeutic outcomes of different
nanoplatforms can be cross-compared for accelerating the
development of effective therapeutic approaches to overcoming
cancer relapse and metastasis. Third, different drugs were
often loaded separately into NPs as loading several drugs into
the same NP is challenging due to different physicochemical
properties of the drugs. Thus, two different NPs of drugs
that are synergistic may not actually reach a particular cell
together, and this may reduce the effectiveness of the therapy.
There is a need to develop multifunctional NPs, which can
load multiple drugs simultaneously with high capacity. Finally,
the toxicity and long-term effects of nanoformulations need
to be studied in depth before they can be used in a clinical
setting.
It will be imperative to gain a better understanding of
the mechanisms involved in the epigenetic regulation of
CSC self-renewal and non-CSC reprogramming. Once the
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mechanism is understood, it can lead to the discovery of
new therapeutic targets and the improvement of current
clinical therapeutic strategies. Currently, new therapies in
the form of NPs-targeting CSC-specific markers or signaling
pathways are available or under investigation. Based on
nanomedicine studies mentioned in our review, it is apparent
that exploiting nanomedicine in treatment of CSCs can lead
to a better outcome for cancer patients. These conclusions
warrant future NPs studies aimed at providing accurate
therapeutic strategies for cancer patients with higher drug
delivery efficiency, more CSC specificity and fewer side
effects.
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